Market closedADR
BioLineRx/$BLRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioLineRx
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Ticker
$BLRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Hevel Modi'in, Israel
Employees
79
Website
BioLineRx Metrics
BasicAdvanced
$40M
Market cap
-
P/E ratio
-$0.03
EPS
0.87
Beta
-
Dividend rate
Price and volume
Market cap
$40M
Beta
0.87
52-week high
$1.93
52-week low
$0.39
Average daily volume
437K
Financial strength
Current ratio
1.609
Quick ratio
1.438
Long term debt to equity
143.759
Total debt to equity
223.553
Interest coverage (TTM)
-12.03%
Management effectiveness
Return on assets (TTM)
-35.23%
Return on equity (TTM)
-171.94%
Valuation
Price to revenue (TTM)
28.411
Price to book
10.55
Price to tangible book (TTM)
508.26
Price to free cash flow (TTM)
-15.906
Growth
Earnings per share change (TTM)
-37.37%
3-year earnings per share growth (CAGR)
-24.92%
What the Analysts think about BioLineRx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioLineRx stock.
BioLineRx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioLineRx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioLineRx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioLineRx stock?
BioLineRx (BLRX) has a market cap of $40M as of November 08, 2024.
What is the P/E ratio for BioLineRx stock?
The price to earnings (P/E) ratio for BioLineRx (BLRX) stock is 0 as of November 08, 2024.
Does BioLineRx stock pay dividends?
No, BioLineRx (BLRX) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next BioLineRx dividend payment date?
BioLineRx (BLRX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioLineRx?
BioLineRx (BLRX) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.